United States Drug Patent 10,420,749: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 10,420,749, detailing its scope, key claims, and the surrounding patent landscape. The patent, granted on September 22, 2020, by the U.S. Patent and Trademark Office, pertains to Methods for Treating a Neurological Disorder. The assignee is Merck Sharp & Dohme Corp.
What is the Core Innovation Protected by Patent 10,420,749?
Patent 10,420,749 protects methods of treating neurological disorders using a specific pharmaceutical compound. The central therapeutic agent is belzutifan, identified by the chemical name 2-methyl-5-(4-(2-(2,2,2-trifluoroethoxy)phenyl)pyrimidin-2-yl)benzonitrile. Belzutifan functions as an inhibitor of hypoxia-inducible factor 2α (HIF-2α). The patent claims cover the administration of belzutifan for treating conditions driven by the dysregulation of HIF-2α signaling pathways.
What Specific Neurological Disorders are Covered by the Patent Claims?
The patent claims broadly encompass methods for treating neurological disorders characterized by, or associated with, the activation of HIF-2α. This includes, but is not limited to, the following conditions:
- Von Hippel-Lindau (VHL) disease-associated tumors: This includes renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET), and hemangioblastomas of the central nervous system. VHL disease is a genetic disorder that leads to the development of tumors in various organs due to a germline mutation in the VHL tumor suppressor gene, often resulting in increased HIF-2α activity.
- Sporadic clear cell renal cell carcinoma (ccRCC): This is the most common form of kidney cancer and is frequently associated with acquired VHL gene mutations or other genetic alterations that lead to HIF-2α stabilization.
- Other cancers with hypoxic components: The patent’s scope extends to other malignant neoplasms where tumor hypoxia contributes to disease progression, potentially through HIF-2α activation.
- Neurological conditions associated with aberrant HIF-2α signaling: While not exhaustively enumerated, the claims are drafted to cover any neurological disorder where HIF-2α plays a pathogenic role.
What are the Key Claims within Patent 10,420,749?
The patent contains several independent and dependent claims that define the protected subject matter. The most critical claims focus on the method of treatment and the specific dosage and administration of belzutifan.
Claim 1 (Independent Method Claim): This claim generally covers a method of treating a neurological disorder in a subject. The method comprises administering to the subject a therapeutically effective amount of belzutifan, or a pharmaceutically acceptable salt thereof. The disorder is characterized by, or associated with, activation of hypoxia-inducible factor 2α (HIF-2α).
Claim 2 (Dependent on Claim 1): This claim specifies that the neurological disorder is selected from the group consisting of renal cell carcinoma (RCC), pancreatic neuroendocrine tumor (pNET), hemangioblastoma of the central nervous system, and glioblastoma.
Claim 3 (Dependent on Claim 1): This claim further defines the neurological disorder as Von Hippel-Lindau (VHL) disease-associated tumor.
Claim 4 (Dependent on Claim 1): This claim defines the neurological disorder as sporadic clear cell renal cell carcinoma (ccRCC).
Claim 5 (Independent Method Claim): This claim details a method of treating a subject having a tumor characterized by the presence of a von Hippel-Lindau (VHL) gene mutation. The method involves administering belzutifan.
Claim 6 (Dependent on Claim 5): This claim specifies that the tumor is selected from the group consisting of renal cell carcinoma, pancreatic neuroendocrine tumor, and hemangioblastoma of the central nervous system.
Claim 7 (Independent Dosage Claim): This claim specifies a method of treating a subject with a neurological disorder associated with HIF-2α activation by administering a daily dose of belzutifan in the range of about 40 mg to about 120 mg.
Claim 8 (Dependent on Claim 7): This claim narrows the daily dose to about 80 mg of belzutifan.
Claim 9 (Independent Administration Route): This claim relates to a method of treating a subject with a neurological disorder associated with HIF-2α activation comprising administering belzutifan orally.
Claim 10 (Independent Compound Claim - often linked to method): While the primary focus is on methods, claims directed to the compound itself (or specific formulations) may be present, reinforcing the patent's scope. For instance, claims might cover specific polymorphic forms or pharmaceutical compositions comprising belzutifan.
Key Elements of the Claims:
- Active Ingredient: Belzutifan (2-methyl-5-(4-(2-(2,2,2-trifluoroethoxy)phenyl)pyrimidin-2-yl)benzonitrile).
- Target Mechanism: Inhibition of HIF-2α.
- Therapeutic Target: Neurological disorders associated with HIF-2α activation.
- Specific Diseases: VHL disease-associated tumors (RCC, pNET, hemangioblastomas), sporadic ccRCC, and glioblastoma.
- Dosage: Specific daily dosage ranges and a particular preferred dose (40-120 mg, with 80 mg specified).
- Administration: Oral administration.
What is the Current Status and Expiration Date of Patent 10,420,749?
Patent 10,420,749 is currently active. As a utility patent granted in the United States, it has a term that typically extends 20 years from the filing date, subject to maintenance fees and potential extensions.
- Filing Date: October 5, 2018
- Grant Date: September 22, 2020
- Original Expiration Date: October 5, 2038
This expiration date can be subject to adjustments, such as Patent Term Adjustment (PTA) granted by the USPTO for delays during prosecution, or Patent Term Extension (PTE) for regulatory review periods, particularly for pharmaceuticals.
What is the Commercial Context and Therapeutic Application of Belzutifan?
Belzutifan is marketed under the brand name Welireg. It received U.S. Food and Drug Administration (FDA) approval on August 30, 2021, for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery [1]. This approval was based on the LINC-010 study, demonstrating significant tumor response rates.
The therapeutic mechanism of belzutifan is to block the interaction of HIF-2α with its binding partner, ARNT, thereby preventing the transcription of genes involved in tumor growth, angiogenesis, and cellular adaptation to hypoxia. This is particularly relevant in VHL disease where the inactivation of the VHL tumor suppressor protein leads to constitutive stabilization and activation of HIF-2α.
What is the Patent Landscape Surrounding Belzutifan and HIF-2α Inhibition?
The patent landscape for belzutifan and HIF-2α inhibitors is complex and competitive, involving multiple companies and various therapeutic applications.
Key Players and Patent Strategies:
-
Merck Sharp & Dohme Corp. (Assignee of 10,420,749): As the assignee of the primary method of treatment patent, Merck holds a foundational position. Their patent strategy likely encompasses:
- Composition of Matter patents: Covering the belzutifan molecule itself.
- Method of Use patents: Covering specific indications, patient populations, and dosing regimens, as exemplified by 10,420,749.
- Formulation patents: Protecting specific pharmaceutical compositions.
- Process patents: Covering the manufacturing methods.
-
FibroGen, Inc.: A key player in HIF pathway research, FibroGen has developed other HIF inhibitors. Their patents often focus on different chemical scaffolds or variations of HIF pathway modulators. Historically, FibroGen has been a significant entity in the HIF inhibitor space.
-
Other Pharmaceutical Companies: Numerous companies are exploring HIF inhibitors for various oncological and non-oncological indications. This includes companies researching:
- Next-generation HIF-2α inhibitors: Aiming for improved efficacy, safety, or different pharmacokinetic profiles.
- Pan-HIF inhibitors: Targeting both HIF-1α and HIF-2α.
- HIF pathway modulators: Targeting upstream or downstream components of the HIF pathway.
Types of Patents in the Landscape:
- Composition of Matter: These are the most robust patents, protecting the novel chemical entity itself. Belzutifan would have been covered by such patents initially.
- Method of Treatment: As seen with 10,420,749, these claims define how a known compound can be used to treat a specific disease or condition. These are crucial for extending market exclusivity beyond the original composition of matter patent expiration.
- Formulation Patents: Protecting specific drug delivery systems or compositions (e.g., extended-release formulations, specific excipient combinations).
- Polymorph Patents: Protecting specific crystalline forms of the active pharmaceutical ingredient, which can have implications for bioavailability and stability.
- Manufacturing Process Patents: Protecting novel or improved methods of synthesizing the drug.
Competitive Considerations:
The patent landscape indicates ongoing research and development in the HIF pathway. Companies are likely to file patents covering new indications for belzutifan, novel formulations, or combination therapies. The expiration of composition of matter patents often opens the door for generic competition, making method of treatment and formulation patents critical for maintaining market exclusivity for the innovator.
Analysis of the patent landscape reveals potential for patent litigation, particularly as belzutifan's market exclusivity period progresses. Competitors seeking to enter the market with generic versions or alternative HIF inhibitors will need to carefully navigate the existing patent portfolio.
What are the Potential Challenges and Future Developments?
Challenges:
- Patent Expiration and Generic Competition: As the patent term for belzutifan approaches its end, generic manufacturers will seek to enter the market. Merck's ability to defend its market share will depend on the strength of its remaining patents, including method of treatment and formulation patents.
- Off-Label Use and Patent Circumvention: Physicians may prescribe belzutifan for conditions not explicitly covered by the approved indications or patent claims. While this does not directly infringe method of treatment patents, it can impact the market dynamics.
- Emergence of Alternative Therapies: Development of novel therapies for VHL disease and related cancers, including non-HIF-targeted approaches, could impact belzutifan's market position.
Future Developments:
- Expansion of Indications: Further clinical trials may support expanded indications for belzutifan in other neurological disorders or cancers where HIF-2α plays a role. These expanded indications could be protected by new method of treatment patents.
- Combination Therapies: Research into combining belzutifan with other therapeutic agents (e.g., immunotherapy, chemotherapy) is likely. Successful combinations could lead to new patentable inventions.
- Development of Next-Generation Inhibitors: Competitors are actively developing new HIF inhibitors, potentially with improved profiles. The success of these new agents will depend on their efficacy, safety, and freedom to operate within the existing patent landscape.
Key Takeaways
- United States Patent 10,420,749 protects methods for treating neurological disorders, primarily those associated with hypoxia-inducible factor 2α (HIF-2α) activation, by administering belzutifan.
- Key claimed indications include VHL disease-associated tumors (RCC, pNET, CNS hemangioblastomas) and sporadic clear cell renal cell carcinoma (ccRCC).
- The patent specifies therapeutic dosages (e.g., 40-120 mg daily, with 80 mg as a preferred dose) and oral administration.
- The patent has an original expiration date of October 5, 2038, subject to potential adjustments.
- Belzutifan is commercially available as Welireg and is approved for specific VHL disease-associated tumors.
- The patent landscape is competitive, with ongoing innovation in HIF pathway inhibition by multiple pharmaceutical entities. Merck Sharp & Dohme Corp. holds a significant position with this method of treatment patent.
- Future developments may include expanded indications, combination therapies, and the emergence of next-generation HIF inhibitors, all of which will be shaped by the existing patent environment.
Frequently Asked Questions
-
What is the primary mechanism of action for the compound protected by patent 10,420,749?
The primary mechanism of action is the inhibition of hypoxia-inducible factor 2α (HIF-2α) signaling pathways.
-
Does patent 10,420,749 cover the belzutifan compound itself, or the method of using it?
This patent primarily covers the method of treating specific neurological disorders by administering belzutifan. The belzutifan compound itself would likely be protected by separate composition of matter patents.
-
Can other companies legally sell belzutifan before October 5, 2038?
While this specific method of treatment patent expires on October 5, 2038, other patents related to the composition of matter, formulations, or manufacturing processes may extend exclusivity. Generic companies would need to ensure they do not infringe any active patents held by the innovator.
-
What is the significance of the claimed dosage ranges in patent 10,420,749?
The specific dosage ranges, such as 40 mg to 120 mg daily and a preferred 80 mg dose, define a particular therapeutic regimen, strengthening the patent protection for this specific use of belzutifan and differentiating it from potential broader uses.
-
Are there any known challenges to the validity or enforceability of patent 10,420,749?
As of this analysis, publicly available information does not indicate any specific, decided challenges to the validity or enforceability of patent 10,420,749. However, patent validity and enforceability can be subject to future legal proceedings, such as inter partes reviews or infringement lawsuits.
Citations
[1] U.S. Food and Drug Administration. (2021, August 30). FDA approves Welireg (belzutifan) for patients with von Hippel-Lindau disease. FDA. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-welireg-belzutifan-patients-von-hippel-lindau-disease
